Alkermes(ALKS) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In 2025, Alkermes generated total revenues of nearly $1.5 billion, with a year-over-year growth of 9% in proprietary product sales, amounting to approximately $1.2 billion in net sales [7][8] - The company recorded GAAP net income of $241.7 million, EBITDA of $285.6 million, and adjusted EBITDA of $394 million for the year [10] - For 2026, total revenues are expected to be in the range of $1.73 billion to $1.84 billion, driven primarily by proprietary product net sales projected between $1.52 billion and $1.6 billion [12] Business Line Data and Key Metrics Changes - VIVITROL net sales for 2025 were $467.9 million, reflecting a 2% growth year-over-year, with expectations for 2026 net sales in the range of $460 million to $480 million [22][23] - ARISTADA net sales were $370 million in 2025, showing a 7% growth year-over-year, with projected 2026 net sales between $365 million and $385 million [24][25] - Bupropion net sales grew 24% year-over-year to $346.7 million in 2025, with expectations for 2026 net sales in the range of $380 million to $400 million [26] Market Data and Key Metrics Changes - LUMRYZ, launched in 2023, generated approximately $279 million in net sales in 2025, with a significant opportunity to expand the patient base as there are an estimated 50,000 oxybate-eligible patients with narcolepsy [27][29] - The company expects LUMRYZ total revenue for 2026 to be in the range of $350 million to $370 million, with an additional $315 million to $335 million expected for the remainder of the year following the acquisition of Avadel [29] Company Strategy and Development Direction - The acquisition of Avadel is seen as a strategic milestone, enhancing Alkermes' entry into the commercial sleep medicine market and providing a platform for the potential launch of alixorexton [4][11] - The company plans to advance its orexin portfolio, including alixorexton, which is expected to enter Phase 3 trials for narcolepsy, and develop ALKS 7290 and ALKS 4510 for ADHD and fatigue associated with neurodegenerative disorders [5][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong financial position and the potential for growth in 2026, emphasizing operational discipline and efficient capital allocation [20][21] - The management team highlighted the importance of the upcoming Phase 3 trials for alixorexton and the integration of Avadel's commercial capabilities as key drivers for future success [30][37] Other Important Information - The company ended 2025 with $1.3 billion in cash and total investments, positioning it well for future growth and debt management following the acquisition [11] - Management announced a leadership transition, with Blair Jackson set to take over as CEO, indicating a commitment to continue the company's growth trajectory [37] Q&A Session Summary Question: Regarding the Phase 3 trial design and AE profile - Management indicated that the orexin 2 receptor agonists have a favorable AE profile and that the split dosing is designed to maximize efficacy while minimizing side effects [41][42] Question: Potential synergies between sales forces post-Avaldel acquisition - Management expressed excitement about the integration of the Avadel team and noted that while there is currently little overlap, future synergies are anticipated as the company prepares to launch alixorexton [44][45] Question: Evidence needed for payers to reimburse both oxybates and orexin agonists - Management explained that both treatments may be necessary for certain patients, and they plan to generate data to support the use of both medications [47][48] Question: Internal benchmarks for ESS in the LUMRYZ Phase 3 trial - Management stated that they expect the data from the upcoming study to mirror previous successful profiles and emphasized the importance of secondary endpoints [52][56] Question: Development plans for Valiloxybate - Management indicated that they are moving forward aggressively with Valiloxybate and will assess the need for additional studies based on early data [84][85]